AstraZeneca Pharma Q4 FY26 Results Preview & Outlook

Wed Mar 25 2026

AstraZeneca Pharma India latest news: AstraZeneca Pharma India Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. AstraZeneca Pharma India was listed on the National Stock Exchange (NSE) on 04-May-2001. AstraZeneca Pharma India share has its face value of 2 per share, and its NSE symbol is ASTRAZEN. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

AstraZeneca Pharma India Q4 Results 2026 Preview

AstraZeneca Pharma India Q4 FY26 revenue is expected to be around Stable Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 12-17% YoY.
EBITDA to rise 14%.
AstraZeneca Pharma India is expected to show Stable Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

AstraZeneca Pharma India Share Performance

Over the past six months, AstraZeneca Pharma India share price has Up by 14-20% to 8401.5.
Moreover, over the past year, the stock has Up by 26%
Despite this weak short-term performance, AstraZeneca Pharma India stock has delivered a financially sound 210% return over the past 5 years.
As of today, 25-03-2026, the AstraZeneca Pharma India share price is trading at 8401.5 per share.

Key Factors to Watch for AstraZeneca Pharma India Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

Visit Univest app or website to check more AstraZeneca Pharma India latest news to make an informed investment decision.

About AstraZeneca Pharma India

AstraZeneca Pharma India develops pharmaceutical products focusing on oncology, cardiovascular, and respiratory therapies. The company benefits from strong parent support and growing healthcare demand.

Visit Univest app or website to check more AstraZeneca Pharma India latest news to make an informed investment decision.

Final Thoughts

AstraZeneca Pharma India is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 12-17% rise in PAT, and a 14% rise in EBITDA. AstraZeneca Pharma India focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on AstraZeneca Pharma India Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.